Eszopiclone Coadministered With Escitalopram in Patients With Insomnia and Comorbid Generalized Anxiety Disorder

Mark Pollack, MD; Gustavo Kinrys, MD; Andrew Krystal, MD; W. Vaughn McCall, MD, MS; Thomas Roth, PhD; Kendyl Schaefer, MS; Robert Rubens, MD, MBA;James Roach, MD; Holly Huang, MS; Ranga Krishnan, MD

context: Insomnia and generalized anxiety disorder (GAD) are prevalent disorders that may coexist. Objective: To determine the efficacy of eszopiclone com­ bined with escitalopram oxalate in treating insomnia co­ morbid with GAD

Objective: To determine the efficacy of eszopiclone com­ bined with escitalopram oxalate in treating insomnia co­ morbid with GAD

Design: Double-blind, randomized, placebo-controlled, parallel-group, add-on therapy 10-week study.

Setting: Multicenter outpatient study from July 2005 to April 2006

Patients: Adults aged 18 to 64 years meeting D5M- IV-TR criteria for GAD and insomnia

Interventions: Patients received 10 mg of escitalo¬ pram oxolate for 10 weeks and were randomized to also receive either 3 mg of eszopiclone (n =294) or placebo (n = 301) nightly for 8 weeks. For the last 2 weeks, es¬ zopiclone was replaced with a single-blind placebo

Pro Vida

Pro Vida

es un  programa  integral,  diseñado  para proveer  diversos  beneficios a pacientes  crónicos. Descuentos  desde su  primera compra, alianzas  con Laboratorios  y  Centro  de Diagnóstico y charlas educacionales al paciente crónico.

Si su médico le ha recetado alguna de las marcas que incluye el programa y  desea obtener todos los beneficios que Provida le ofrece, favor comunicarse al Call Center, para afiliarse y ser parte del programa.

Productos destacados

It seems we can't find what you're looking for.